

Prevalence of quinolone-resistant uropathogenic *Escherichia coli* in a tertiary care hospital in south Iran

This article was published in the following Dove Press journal:
Infection and Drug Resistance

Yalda Malekzadegan¹
Elham Rastegar¹
Melika Moradi¹
Hamid Heidari²
Hadi Sedigh Ebrahim-
Saraie³

¹Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; ²Department of Microbiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; ³Razi Clinical Research Development Center, Guilan University of Medical Sciences, Rasht, Iran

Background: Quinolones are a family of synthetic antimicrobial agents with a broad antibacterial activity commonly used as a suitable therapy in patients with urinary tract infection (UTI). In the present study, we aimed to evaluate the prevalence of quinolones resistance and the presence of plasmid-mediated quinolone resistance (PMQR) genes among *Escherichia coli* isolates.

Methods: This study was performed on a collection of 121 *E. coli* isolates derived from patients with UTI. Antimicrobial susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, norfloxacin, and ofloxacin was specified by the disk diffusion method. The presence of PMQR genes was determined by PCR method.

Results: Antibiotic susceptibility results showed that the highest and lowest resistance rates were against nalidixic acid (71.9%) and norfloxacin (44.6%), respectively. The molecular results showed that 40 (33.1%) and 15 (12.4%) of the isolates were positive for *qnrS* and *qnrB* genes, respectively. Meanwhile, 5 (4.1%) of the isolates were found positive for both genes, while none were found to be positive for *qnrA* gene. There was no significant association between the presence of *qnr* genes and higher antibiotic resistance.

Conclusion: We found high levels of quinolones resistance (more than 40%) among *E. coli* strains isolated from patients with UTIs in the south of Iran. We further report the prevalence of PMQR genes among uropathogenic *E. coli*; however, it seems that these genes are not the main components of quinolone resistance in our region.

Keywords: urinary tract infection, *Escherichia coli*, quinolone, antibiotic resistance

Introduction

Among the wide range of uropathogens conducting to the development of urinary tract infections (UTIs), uropathogenic *Escherichia coli* (UPEC) strains are considered as the main causative agents.¹ UPEC account for the preponderance of both community- and hospital-acquired UTIs.¹ Several risk factors including renal diseases increase the risk of UTI; however, the treatment of infection more often do not require antimicrobial therapy.^{2,3} Over the recent years, antibiotic therapy of UTI has become problematic due to the misuse and irregular consumption of antibiotics entailing the emergence of resistant strains.⁴ *E. coli* may be resistant to various types of antibiotics and act in different ways to transfer antibiotic resistance genes to other strains and bacteria such as transposon, bacteriophage, and plasmid.⁵

Quinolones are a family of synthetic antimicrobial agents with a broad antibacterial activity commonly used as a suitable therapy in patients with UTI.^{6,7} This

Correspondence: Hadi Sedigh Ebrahim-Saraie
Razi Clinical Research Development Center, Razi Hospital, Sardar-E-Jangal Street, Rasht, Guilan, Iran
Tel +980 133 354 2460
Fax +980 133 354 2460
Email seddigh.hadi@gmail.com

family has been classified into four generations based on their antimicrobial activity. The most well-known quinolone antibiotics are nalidixic acid, ciprofloxacin, and levofloxacin as members of the first, second, and third generations, respectively.⁶ Quinolones prevent bacterial DNA synthesis through inhibiting DNA gyrase and topoisomerase IV enzymes leading to cell death.⁸ Quinolone resistance is caused by various mechanisms, particularly plasmid-mediated quinolone resistance (PMQR) which contains the pentapeptide repeat family Qnr proteins (QnrA, QnrB, QnrS, QnrC, and QnrD). These proteins confer quinolone resistance by physically protecting DNA gyrase and topoisomerase IV from quinolone acts.⁸ This condition may provide a selective advantage for the development of quinolone resistance which could result in therapeutic failure.⁹

Due to the high horizontal gene transferring capability of *E. coli*, it is necessary to estimate the burden and control the spread of quinolone-resistant strains in hospitals. In this study, we aimed to evaluate the prevalence of quinolones resistance and the presence of PMQR genes in *E. coli* strains isolated from Iranian patients with UTI, in order to categorize the genes with a more significant role in the development of resistance to quinolones in our region.

Materials and methods

Study design and *Escherichia coli* samples

This study was performed on a collection of 121 non-duplicated *E. coli* isolates (one per patient) derived from patients with UTI in our previous work.¹⁰ Samples were collected from November 2016 to May 2017 from inpatients who presented with symptomatic UTI at a tertiary care hospital (Nemazee) in Shiraz, the south of Iran. The patients had not received antibiotics at least one week before the sample collection. The mixed growth of bacteria was considered as contamination and was excluded. The study design was in accordance with the declaration of Helsinki and ethical permission was sought previously from the institutional Ethics Committee of Shiraz University of Medical Sciences (Approval No. IR.SUMS.REC.1395.S747). However, because only leftovers from clinical specimens were used, the local ethics committee waived the need for informed consent. *E. coli* isolates were identified by standard microbiological tests and API 20E strip (API-bioMérieux, France). Confirmed *E. coli* isolates were preserved at -80°C for further works.

Quinolones susceptibility testing

The susceptibility of isolates toward five quinolone antibiotics including nalidixic acid, ciprofloxacin, levofloxacin, norfloxacin, and ofloxacin was investigated by standard disk diffusion technique on Muller-Hinton agar (Merck, Germany) plates according to the clinical and laboratory standards institute (CLSI) guidelines.¹¹ All antibiotic disks were provided from Mast Co., UK. The plates were then incubated at 37°C for 16–18 hrs. *E. coli* ATCC 25922 was used as a quality control strain for antibiotic susceptibility testing. Based on antibiotic susceptibility results, fluoroquinolones resistant and nalidixic acid non-susceptible (resistant or intermediate) isolates were classified as high-level quinolone-resistant bacteria.¹² Extended spectrum β -lactamases (ESBLs) production was tested using the double-disk synergy test elsewhere.¹⁰

Detection of Qnr encoding genes

The bacterial whole genome was extracted by the boiling method as previously described.¹³ Polymerase chain reaction (PCR) assays were performed for the detection of *qnr* resistance genes including *qnrA*, *qnrB*, and *qnrS*. The primers used to detect *qnr* genes were selected from previously described sequences by Cattoirin and colleagues.¹⁴ PCR was done in a total volume of 25 μL containing 3 μL DNA template, 2.5 μL PCR buffer (1X), 1 μL deoxyribonucleotide triphosphates solution (dNTPs, 200 μM), 1.5 μL MgCl_2 (1.5 mM), 0.25 μL Taq DNA polymerase (1 Unit), and 1 μL each specific primers (1 μM). PCR amplifications for the studied genes were carried out on a T100™ thermal cycler (Bio-Rad, Hercules, CA, USA). The cycling conditions were set up as follows: 95°C for 5 mins (step 1), 95°C for 1 min (step 2), annealing for 45 sec (step 3), 72°C for 1 min (step 4), and 72°C for 5 mins (step 5); steps 2–4 were repeated for 30 cycles. The amplifications were separated on 1.5% agarose gel prepared in 1X TAE (Tris/Acetate/EDTA) buffer and visualized using ultraviolet light after staining with safe stain load dye (CinnaGen Co., Iran).

Statistical analysis

The analysis was performed through the use of SPSS™ software, version 21.0 (IBM Corp., USA). The results are presented as descriptive statistics in terms of relative frequency. Categorical variables were expressed as counts and percentages. The Chi-square (χ^2) or Fisher's exact

tests were performed to analyze significant differences. AP -value <0.05 was considered as statistically significant.

Results

Analysis of antibiotic susceptibility tests showed that the highest and lowest resistance rates were against nalidixic acid (71.9%) and norfloxacin (44.6%), respectively. The full results of antibiotic susceptibility assay for *E. coli* isolates are shown in Table 1. Moreover, 60 (49.6%) of *E. coli* isolates were classified as high-level quinolone-resistant.

The molecular results showed that 40 (33.1%) and 15 (12.4%) of the isolates were positive for *qnrS* and *qnrB* genes, respectively (Figure 1). Meanwhile, 5 (4.1%) of the isolates were found positive for both genes, while none were found to be positive for *qnrA* gene. In addition, 50 (41.3%) of the isolates were *qnr* positive. The distribution of *qnr*-positive isolates in different hospital units was almost the same; however, the positivity rate in the transplant unit was high (Data not shown).

There was no significant association between *qnr* genes and higher antibiotic resistance. However, *qnrS* gene was found to be relatively higher than *qnrB* gene among antibiotic-resistant isolates (Table 2). Meanwhile, it seems that

qnr genes are more likely to occur in nalidixic acid resistant rather than fluoroquinolones-resistant isolates.

Of totally 51 ESBLs producing isolates, 14 (25.7%) and 6 (11.8%) isolates contained *qnrS* and *qnrB* genes, respectively. Distribution of *qnr* genes among ESBLs-producing isolates in relation to quinolones susceptibility is presented in Table 3. The proportion of *qnrS* gene among ESBLs-producing quinolone-resistant isolates compared to susceptible isolates was relatively high, but the differences were not statistically significant. The proportion of *qnrB* gene was more prevalent among ESBLs-producing quinolone-susceptible isolates.

Discussion

The extensive use of quinolone antibiotics in poultry production and human medicine is associated with the increasing emergence of quinolone-resistant strains.⁸ Here, we investigated the quinolones resistance among a collection of UPEC in one of the largest tertiary care hospitals in the south of Iran in order to inform physicians as to the regional antibiotic resistance rates and further conduce to the international data to ameliorate antimicrobial stewardship programs. In the present study, the rate of quinolones resistance exceeded 40%, which discourages the empirical use of quinolones in our region since the risk of treatment failure increases when resistance rates exceed 10% to 20%.^{15,16} However, the evidence is insufficient to make a recommendation against using quinolones since no alternative oral antimicrobial options are available for the treatment of pyelonephritis.¹⁷ Currently, the incidence of trimethoprim-sulfamethoxazole and amoxicillin-clavulanate resistant *E. coli* approach or exceed from quinolones-resistant rate depending on the geographical region.¹⁸ Other oral

Table 1 The antibiotic susceptibility testing results of 121 *E. coli* isolates

Antibiotic	Resistant No. (%)	Intermediate-resistant No. (%)	Susceptible No. (%)
Nalidixic acid	87 (71.9)	11 (9.1)	23 (19)
Ciprofloxacin	59 (48.4)	12 (9.9)	50 (41.3)
Levofloxacin	58 (47.9)	3 (2.5)	60 (49.6)
Ofloxacin	56 (46.3)	4 (3.3)	61 (50.4)
Norfloxacin	54 (44.6)	5 (4.1)	62 (51.2)




Figure 1 Agarose gel electrophoresis of PCR products for *qnrB* and *qnrS* genes. M: 100 bp DNA size marker.

Table 2 Distribution of *qnr* genes in relation with quinolone resistance

Antibiotic	Pattern	<i>qnrS</i> -positive No. (%)	<i>qnrS</i> -negative No. (%)	P-value	<i>qnrB</i> -positive No. (%)	<i>qnrB</i> -negative No. (%)	P-value
Nalidixic acid	R ^a (n=98)	34 (34.7)	64 (65.3)	0.430	10 (10.2)	88 (89.8)	0.131
	S (n=23)	6 (26.1)	17 (73.9)		5 (21.7)	18 (78.3)	
Ciprofloxacin	R (n=71)	21 (29.6)	50 (70.4)	0.332	2 (2.8)	69 (97.2)	<0.001
	S (n=50)	19 (38)	31 (62)		13 (26.2)	37 (74)	
Levofloxacin	R (n=61)	16 (26.2)	45 (73.8)	0.107	2 (3.3)	59 (96.7)	0.002
	S (n=60)	24 (40)	36 (60)		13 (21.7)	47 (78.3)	
Ofloxacin	R (n=60)	15 (25)	45 (75)	0.062	3 (5)	57 (95)	0.014
	S (n=61)	25 (41)	36 (59)		12 (19.7)	49 (80.3)	
Norfloxacin	R (n=98)	14 (23.7)	45 (76.3)	0.033	2 (3.4)	57 (96.6)	0.003
	S (n=23)	26 (41.9)	36 (58.1)		13 (21)	49 (79)	

Notes: ^aIncluding resistant and intermediate-resistant isolates.

Abbreviations: R, Resistant; S, Susceptible.

Table 3 Distribution of *qnr* genes among 51 ESBLs producing isolates

Antibiotic	Pattern	<i>qnrS</i> -positive No. (%)	<i>qnrS</i> -negative No. (%)	P-value	<i>qnrB</i> -positive No. (%)	<i>qnrB</i> -negative No. (%)	P-value
Nalidixic acid	R ^a (n=45)	13 (28.9)	32 (71.1)	0.468	4 (8.9)	41 (91.1)	0.141
	S (n=6)	1 (16.7)	5 (83.3)		2 (33.3)	4 (66.7)	
Ciprofloxacin	R (n=38)	11 (28.9)	27 (71.1)	0.492	2 (5.3)	36 (94.7)	0.031
	S (n=13)	3 (23.1)	10 (76.9)		4 (30.8)	9 (69.2)	
Levofloxacin	R (n=34)	10 (29.4)	24 (70.6)	0.463	2 (5.9)	32 (94.1)	0.087
	S (n=17)	4 (23.5)	13 (76.5)		4 (23.5)	13 (76.5)	
Ofloxacin	R (n=33)	9 (27.3)	24 (72.7)	0.608	2 (6.1)	31 (93.9)	0.106
	S (n=18)	5 (27.8)	13 (72.2)		4 (22.2)	14 (77.8)	
Norfloxacin	R (n=31)	7 (22.6)	24 (77.4)	0.257	2 (6.5)	29 (93.5)	0.154
	S (n=20)	7 (35)	13 (65)		4 (20)	16 (80)	

Notes: ^aIncluding resistant and intermediate-resistant isolates.

Abbreviations: R, Resistant; S, Susceptible.

agents such as cephalosporins, nitrofurantoin, and fosfomycin are not recommended for treatment of pyelonephritis.¹⁹ Also, a high drug concentration of quinolones in urine can affect clinical outcomes of patients with UTIs even those infected by resistant strains.¹⁷ So, quinolones remain an important treatment option for empirical therapy of complicated urinary tract infections (cUTIs), particularly after stratification of patients based on predicted risk of antimicrobial resistance.²⁰

The literature review indicates a high prevalence of quinolones resistance in Iran. In 2014, Pouladfar et al showed that 38.5% and 75% of *E. coli* isolates causing UTI in children (in Shiraz) were resistant to ciprofloxacin and nalidixic acid, respectively, which is very close to the findings of the present research.²¹ Shenagari et al (2017) showed 45.3% resistance to norfloxacin, 48.9% to ofloxacin, 50.2% to ciprofloxacin, and 61.9% to nalidixic acid among their UPEC in Rasht (North of Iran).²² Rezazadeh et al (2014–2015) found 55.5% resistance to norfloxacin, 56% to ciprofloxacin, 56% to levofloxacin, 58% to gatifloxacin, and 66.5% to nalidixic acid among *E. coli* strains isolated from UTI patients in Qazvin (North of Iran) and Zanjan (Northwest of Iran).²³ Damavandi et al (2013 to 2014) observed 45% resistance to norfloxacin, 48% to ciprofloxacin, and 62% to nalidixic acid in the *E. coli* strains isolated from the inpatients of Shahrekord (central Iran).²⁴ In contrast to our findings, Sedighi et al (2010 to 2011) found 14.2% resistance to ofloxacin, 15% to norfloxacin, 15% to ciprofloxacin, and 40.9% to nalidixic acid among their UPEC strains in Hamadan (central Iran).²⁵ Moreover, a recent systematic review and meta-analysis study has shown that ciprofloxacin-resistant *E. coli* in UTI is a global problem, where Asia has the highest pooled resistance (50%).²⁶

Such a high prevalence of quinolone resistance may be linked to dissemination of multidrug-resistant (MDR) extraintestinal pathogenic *E. coli* (ExPEC) isolates.²⁷ Recent data from Iran suggest that *E. coli* sequence type (ST) 131 has emerged as an important public health concern.^{28–30} This pandemic clone which was recognized since 2000 is strongly associated with ESBLs, fluoroquinolone, trimethoprim-sulfamethoxazole, and third-generation cephalosporins resistance.^{27,31}

In the present study, 41.3% of the isolates contained *qnr* encoding genes, mainly *qnrS*. However, no significant association was observed between the presence of *qnr* genes and quinolone resistance. It seems that the *Qnr* family is not the main mechanism of quinolone resistance in *E. coli* in our region, and other mechanisms such as

point mutations in the *gyrA* and *parC* genes may play a role.⁸ However, it is supposed that PMQR genes can be clinically important as they facilitate the selection of higher levels of quinolone resistance.³² In this regard, there are several comparable reports pointing to the prevalence of *qnr* genes among *E. coli* isolates. Yousefi et al found a high prevalence of *qnrB* (71.3%) and *qnrS* (62.8%) genes with a significant association with quinolone resistance among UPEC strains in the north of Iran.³³ Sedighi et al found *qnrB* in 6.7% and *qnrS* in 5% of UPEC strains and a significant association between the quinolone resistance and presence of *qnr* genes.²⁵ Rezazadeh et al observed a low level of *qnrS1* gene among quinolone-resistant *E. coli* isolates, while *qnrA* and *qnrB* genes were not found in any of the isolates.²³ In yet another study, Abbasi et al showed the prevalence of *qnrS* (36%) and *qnrB* (25%) as the only detected *qnr* genes among *E. coli* strains isolated from UTIs in Tehran.³⁴ Despite the relative agreement on the higher prevalence of *qnrS* and *qnrB* genes among UPEC, the distribution of predominate genes is varied over different regions. These variations in results are consistent with observations from other Asian countries such as Iraq,³⁵ Pakistan,³⁶ Saudi Arabia,³⁷ Korea,³⁸ Taiwan,³⁹ and China.⁴⁰

The present study encountered certain limitations such as lack of investigation on other quinolone resistance mechanisms. Furthermore, due to the lack of a molecular typing method, there was no mention of the genetic relatedness of the quinolone-resistant strains.

Conclusion

In summary, we found a high level of quinolones resistance (more than 40%) among *E. coli* strains isolated from patients with UTI in the south of Iran. Rational use of antimicrobial policy as well as stopping the unnecessary prescription and non-prescription sales in retail pharmacies can be performed as strategies to prevent the increase of quinolones resistance. As the first preliminary survey, we further report the prevalence of PMQR genes among UPEC, while it seems that these genes are not the main mechanism of quinolone resistance. However, further studies are required to investigate all other possible mechanisms in larger series.

Acknowledgment

The authors wish to thank Ms. N. Zahedian Nezhad for her invaluable assistance in samples collection.

Author contributions

All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Terlizzi ME, Gribaudo G, Maffei ME. UroPathogenic *Escherichia coli* (UPEC) infections: virulence factors, bladder responses, antibiotic, and non-antibiotic antimicrobial strategies. *Front Microbiol*. 2017;8:1566. doi:10.3389/fmicb.2017.01566
2. Hemmati H, Khosravi M, Heidarzadeh A, Hashkavaei P, Refahibakhsh N. Vascular access and survival in hemodialysis patients in Rasht, Iran. *Iran J Kidney Dis*. 2011;5(1):34–37.
3. John U, Kemper MJ. Urinary tract infections in children after renal transplantation. *Pediatr Nephrol*. 2009;24(6):1129–1136. doi:10.1007/s00467-007-0690-0
4. Tenney J, Hudson N, Alnifaity H, Li JTC, Fung KH. Risk factors for acquiring multidrug-resistant organisms in urinary tract infections: a systematic literature review. *Saudi Pharm J*. 2018;26(5):678–684. doi:10.1016/j.jsps.2018.02.023
5. Munita JM, Arias CA. Mechanisms of antibiotic resistance. *Microbiol Spectr*. 2016;4:2.
6. King DE, Malone R, Lilley SH. New classification and update on the quinolone antibiotics. *Am Fam Physician*. 2000;61(9):2741–2748.
7. Tayebi Z, Heidari H, Kazemian H, Ghafoori SM, Boroumandi S, Hourri H. Comparison of quinolone and beta-lactam resistance among *Escherichia coli* strains isolated from urinary tract infections. *Infez Med*. 2016;24(4):326–330.
8. Correia S, Poeta P, Hebraud M, Capelo JL, Igrejas G. Mechanisms of quinolone action and resistance: where do we stand? *J Med Microbiol*. 2017;66(5):551–559. doi:10.1099/jmm.0.000475
9. Jacoby GA. Mechanisms of resistance to quinolones. *Clin Infect Dis*. 2005;41(Suppl 2):S120–126. doi:10.1086/444499
10. Ebrahim-Saraie HS, Nezhad NZ, Heidari H, Motamedifar A, Motamedifar M. Detection of antimicrobial susceptibility and integrons among extended-spectrum beta-lactamase producing uropathogenic *Escherichia coli* isolates in Southwestern Iran. *Oman Med J*. 2018;33(3):218–223. doi:10.5001/omj.2018.40
11. CLSI. *Performance Standards for Antimicrobial Susceptibility Testing: 28th Informational Supplement*. CLSI Document M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2018:2018.
12. Oktem IM, Gulay Z, Bicmen M, Gur D. qnrA prevalence in extended-spectrum beta-lactamase-positive enterobacteriaceae isolates from Turkey. *Jpn J Infect Dis*. 2008;61(1):13–17.
13. Nobari S, Shahcheraghi F, Rahmati Ghezalgh F, Valizadeh B. Molecular characterization of carbapenem-resistant strains of *klebsiella pneumoniae* isolated from Iranian patients: first identification of blaKPC gene in Iran. *Microb Drug Resist*. 2014;20(4):285–293. doi:10.1089/mdr.2013.0074
14. Cattoir V, Poirel L, Rotimi V, Soussy CJ, Nordmann P. Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. *J Antimicrob Chemother*. 2007;60(2):394–397. doi:10.1093/jac/dkm215
15. McQuiston Haslund J, Rosborg Dinesen M, Sternhagen Nielsen AB, Llor C, Bjerrum L. Different recommendations for empiric first-choice antibiotic treatment of uncomplicated urinary tract infections in Europe. *Scand J Prim Health Care*. 2013;31(4):235–240. doi:10.3109/02813432.2013.844410
16. Bidell MR, Palchak M, Mohr J, Lodise TP. Fluoroquinolone and third-generation-cephalosporin resistance among hospitalized patients with urinary tract infections due to *Escherichia coli*: do rates vary by hospital characteristics and geographic region? *Antimicrob Agents Chemother*. 2016;60(5):3170–3173. doi:10.1128/AAC.02505-15
17. Kim ES, Hooper DC. Clinical importance and epidemiology of quinolone resistance. *Infect Chemother*. 2014;46(4):226–238. doi:10.3947/ic.2014.46.4.226
18. Bryce A, Hay AD, Lane IF, Thornton HV, Wootton M, Costelloe C. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by *Escherichia coli* and association with routine use of antibiotics in primary care: systematic review and meta-analysis. *Bmj*. 2016;352:i939. doi:10.1136/bmj.i1717
19. Carson C, Naber KG. Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections. *Drugs*. 2004;64(12):1359–1373. doi:10.2165/00003495-200464120-00007
20. Shah A, Justo JA, Bookstaver PB, Kohn J, Albrecht H, Al-Hasan MN. Application of fluoroquinolone resistance score in management of complicated urinary tract infections. *Antimicrob Agents Chemother*. 2017;61:5. doi:10.1128/AAC.02313-16
21. Pouladfar G, Basiratnia M, Anvarinejad M, Abbasi P, Amirmoezi F, Zare S. The antibiotic susceptibility patterns of uropathogens among children with urinary tract infection in Shiraz. *Medicine (Baltimore)*. 2017;96(37):e7834. doi:10.1097/MD.0000000000007834
22. Shenagari M, Bakhtiari M, Mojtahedi A, Atrkar Roushan Z. High frequency of mutations in gyrA gene associated with quinolones resistance in uropathogenic *Escherichia coli* isolates from the north of Iran. *Iran J Basic Med Sci*. 2018;21(12):1226–1231.
23. Rezazadeh M, Baghchesaraei H, Peymani A. Plasmid-mediated quinolone-resistance (qnr) genes in clinical isolates of *Escherichia coli* collected from several hospitals of Qazvin and Zanjan Provinces, Iran. *Osong Public Health Res Perspect*. 2016;7(5):307–312. doi:10.1016/j.phrp.2016.08.003
24. Damavandi MS, Gholipour A, Latif Pour M. Prevalence of class D carbapenemases among extended-spectrum beta-lactamases producing *Escherichia coli* isolates from educational hospitals in Shahrekord. *J Clin Diagn Res*. 2016;10(5):Dc01–05.
25. Sedighi I, Arabestani MR, Rahimbakhsh A, Karimitabar Z, Alikhani MY. Dissemination of extended-spectrum beta-lactamases and quinolone resistance genes among clinical isolates of uropathogenic *Escherichia coli* in children. *Jundishapur J Microbiol*. 2015;8(7):e19184. doi:10.5812/jjm.19184v2
26. Fasugba O, Gardner A, Mitchell BG, Mnataganian G. Ciprofloxacin resistance in community- and hospital-acquired *Escherichia coli* urinary tract infections: a systematic review and meta-analysis of observational studies. *BMC Infect Dis*. 2015;15:545. doi:10.1186/s12879-015-1282-4
27. McNally A, Kallonen T, Connor C, et al. Diversification of colonization factors in a multidrug-resistant *Escherichia coli* lineage evolving under negative frequency-dependent selection. *MBio*. 2019;10(2):e00644–00619. doi:10.1128/mBio.00669-19
28. Hojabri Z, Mirmohammadkhani M, Kamali F, Ghassemi K, Taghavipour S, Pajand O. Molecular epidemiology of *Escherichia coli* sequence type 131 and its H30/H30-Rx subclones recovered from extra-intestinal infections: first report of OXA-48 producing ST131 clone from Iran. *Eur J Clin Microbiol Infect Dis*. 2017;36(10):1859–1866. doi:10.1007/s10096-017-3021-9
29. Moghanni M, Ghazvini K, Farsiani H, et al. High prevalence of sequence type 131 isolates producing CTX-M-15 among extended-spectrum beta-lactamase-producing *Escherichia coli* strains in northeast Iran. *J Glob Antimicrob Resist*. 2018;15:74–78. doi:10.1016/j.jgar.2018.05.016
30. Namaei MH, Yousefi M, Ziaee M, et al. First Report of prevalence of CTX-M-15-producing *Escherichia coli* O25b/ST131 from Iran. *Microb Drug Resist*. 2017;23(7):879–884. doi:10.1089/mdr.2016.0069

31. Badran EF, Qamer Din RA, Shehabi AA. Low intestinal colonization of *Escherichia coli* clone ST131 producing CTX-M-15 in Jordanian infants. *J Med Microbiol*. 2016;65(2):137–141. doi:10.1099/jmm.0.000210
32. Jacoby GA, Strahilevitz J, Hooper DC. Plasmid-mediated quinolone resistance. *Microbiol Spectr*. 2014;2:5. doi:10.1128/microbiolspec.PLAS-0006-2013
33. Yousefi S, Mojtahedi A, Shenagari MA. Survey of *gyrA* target-site mutation and *qnr* genes among clinical isolates of *Escherichia coli* in the North of Iran. *Jundishapur J Microbiol*. 2018;11(9):e67293. doi:10.5812/jjm.67293
34. Abbasi H, Ranjbar R. The prevalence of quinolone resistance genes of A, B, S in *Escherichia coli* strains isolated from three major hospitals in Tehran, Iran. *Cent European J Urol*. 2018;71(1):129–133.
35. Al-Hasnawy HH, Jodi MR, Hamza HJ. Molecular characterization and sequence analysis of plasmid-mediated quinolone resistance genes in extended-spectrum beta-lactamases producing uropathogenic *Escherichia coli* in Babylon Province, Iraq. *Rev Med Microbiol*. 2018;29(3):129–135. doi:10.1097/MRM.0000000000000136
36. Ali I, Rafaque Z, Ahmed S, Malik S, Dasti JI. Prevalence of multi-drug resistant uropathogenic *Escherichia coli* in Potohar region of Pakistan. *Asian Pac J Trop Biomed*. 2016;6(1):60–66. doi:10.1016/j.apjtb.2015.09.022
37. Al-Agamy MH, Aljallal A, Radwan HH, Shibl AM. Characterization of carbapenemases, ESBLs, and plasmid-mediated quinolone determinants in carbapenem-insensitive *Escherichia coli* and *Klebsiella pneumoniae* in Riyadh hospitals. *J Infect Public Health*. 2018;11(1):64–68. doi:10.1016/j.jiph.2017.03.010
38. Shin JH, Jung HJ, Lee JY, Kim HR, Lee JN, Chang CL. High rates of plasmid-mediated quinolone resistance *QnrB* variants among ciprofloxacin-resistant *Escherichia coli* and *Klebsiella pneumoniae* from urinary tract infections in Korea. *Microb Drug Resist*. 2008;14(3):221–226. doi:10.1089/mdr.2008.0834
39. Kao CY, Wu HM, Lin WH, et al. Plasmid-mediated quinolone resistance determinants in quinolone-resistant *Escherichia coli* isolated from patients with bacteremia in a university hospital in Taiwan, 2001–2015. *Sci Rep*. 2016;6:32281. doi:10.1038/srep32281
40. Zhao L, Zhang J, Zheng B, et al. Molecular epidemiology and genetic diversity of fluoroquinolone-resistant *Escherichia coli* isolates from patients with community-onset infections in 30 Chinese county hospitals. *J Clin Microbiol*. 2015;53(3):766–770. doi:10.1128/JCM.02594-14

Infection and Drug Resistance

Dovepress

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>